Get started
Author

Dominik Maurer

Actively personalized vaccination trial for newly diagnosed glioblastoma
2018 · Norbert Hilf, Sabrina Kuttruff-Coqui, et al. · Nature · 948
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
2012 · Steffen Walter, Toni Weinschenk, et al. · Nature Medicine · 802
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
2016 · Brian I Rini, Arnulf Stenzl, et al. · The Lancet Oncology · 228
Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study
2016 · Susanna Mandruzzato, Sven Brandau, et al. · Cancer Immunology Immunotherapy · 207
PDF
Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial
2025 · Martin Wermke, Dejka M. Araujo, et al. · Nature Medicine · 78
Thinking Outside the Gate: Single-Cell Assessments in Multiple Dimensions
2015 · Pia Kvistborg, Cécile Gouttefangeas, et al. · Immunity · 61
PDF
Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen presenting cells
2007 · Despina Rudolf, Tobias Silberzahn, et al. · Cancer Immunology Immunotherapy · 59
A Cryptic Vascular Endothelial Growth Factor T-Cell Epitope: Identification and Characterization by Mass Spectrometry and T-Cell Assays
2008 · Andreas O. Weinzierl, Dominik Maurer, et al. · Cancer Research · 51
PDF
Quantitative immunopeptidomics reveals a tumor stroma–specific target for T cell therapy
2022 · Gloria B. Kim, Jens Fritsche, et al. · Science Translational Medicine · 41
PDF
High-throughput peptide-MHC complex generation and kinetic screenings of TCRs with peptide-receptive HLA-A*02:01 molecules
2019 · Andreas Moritz, Raghavendra Anjanappa, et al. · Science Immunology · 40
Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8+ T cells with detection by ELISPOT and HLA-multimer staining
2014 · Lindsey Chudley, Katy J. McCann, et al. · Cancer Immunology Immunotherapy · 39
PDF
Identification of HLA-A*01- and HLA-A*02-restricted CD8+ T-cell epitopes shared among group B enteroviruses
2008 · Andreas O. Weinzierl, Despina Rudolf, et al. · Journal of General Virology · 24
Cryopreservation of MHC multimers: Recommendations for quality assurance in detection of antigen specific T cells
2014 · Sine Reker Hadrup, Dominik Maurer, et al. · Cytometry Part A · 23
PDF
17LBA Results from an open-label, randomized, controlled Phase 3 study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic RCC
2015 · B. Rini, A. Stenzl, et al. · European Journal of Cancer · 20
959 Safety and anti-tumor activity of TCR-engineered autologous, PRAME-directed T cells across multiple advanced solid cancers at low doses – clinical update on the ACTengine® IMA203 trial
2021 · Martin Wermke, Apostolia-Maria Tsimberidou, et al. · Journal for ImmunoTherapy of Cancer · 18
PDF
Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2023 · Apostolia M. Tsimberidou, Kerstin Guenther, et al. · Cancer Immunology Research · 16
PDF
Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma
2019 · Norbert Hilf, Sabrina Kuttruff-Coqui, et al. · Nature · 15
PDF
An ultra-high-throughput screen for the evaluation of peptide HLA-Binder interactions
2023 · Stefan Krämer, Andreas Moritz, et al. · Scientific Reports · 10
PDF
SARS‐CoV‐2‐reactive T‐cell receptors isolated from convalescent COVID‐19 patients confer potent T‐cell effector function
2021 · Fabian Brunk, Andreas Moritz, et al. · European Journal of Immunology · 10
PDF
Development of an RNA-based kit for easy generation of TCR-engineered lymphocytes to control T-cell assay performance
2018 · Nicole Bidmon, Sonja Kind, et al. · Journal of Immunological Methods · 8
PDF
Author Correction: Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial
2025 · Martin Wermke, Dejka M. Araujo, et al. · Nature Medicine · 7
PDF
Effective Targeting of PRAME-Positive Tumors with Bispecific T Cell-Engaging Receptor (TCER®) Molecules
2019 · Sebastian Bunk, Martin Hofmann, et al. · Blood · 7
Immune responses and association with clinical outcome of advanced colorectal cancer patients treated with the multi-peptide vaccine IMA910.
2012 · Sabrina Kuttruff, Toni Weinschenk, et al. · Journal of Clinical Oncology · 6
Correlation of immune responses with survival in a randomized phase II study investigating multipeptide vaccination with IMA901 plus or minus low-dose cyclophosphamide in advanced renal cell carcinoma (RCC).
2010 · H. Singh, N. Hilf, et al. · Journal of Clinical Oncology · 5
IMA402, an Off-the-Shelf, Next-Generation TCR Bispecific (TCER®) for Efficiently Targeting an HLA-Presented Peptide from the Pan-Cancer Antigen PRAME
2022 · Sebastian Bunk, Martin Hofmann, et al. · Blood · 4
Works count: 122
Citation count: 2,737
H-index: 16
I10-index: 19
Year
Topic
Type